Frequency and Distribution of Rifampicin Resistance in Mycobacterium Tuberculosis Clinical Isolates Using Gene Xpert MTB/RIF in Delta State, South-South Nigeria

Abstract

The emergence and spread of multi-drug resistant-tuberculosis is a threat, which has complicated the diagnosis, management and control of tuberculosis. In addition to the simultaneous detection of Mycobacterium tuberculosis bacilli and rifampicin resistance, the Gene Xpert assay can also highlight the point of mutation if it occurs around the rifampicin resistance determination region (RRDR) of the rpoB gene, which is responsible for 95% of rifampicin resistance. This study seeks to estimate the prevalence of rifampicin resistance, determine the frequency and distribution of mutations along the rifampicin resistance determination region, and assay for the relationship that exists between these mutations and basic epidemiological variables.

Evaluation of immunoglobulin M and A level in individuals with HIV-TB co-infection in NAUTH, Nnewi

“…This agrees with previous reports indicating that both pathogens affect mostly individuals in their economically productive years. 5 Nigeria still ranks among the eight countries listed as being responsible for two-thirds of the total global TB burden 10 with high prevalence reported in various parts of Nigeria 12 and HIV prevalence among adults in Nigeria recorded at 3.2%. 23 The mean total serum levels of IgA and IgMin TB, HIV-TB co-infection, HIV and control participants were significantly elevated variably.…”

“…11 Notably Nigeria ranks among the eight countries listed as being responsible for two thirds of the total global TB burden 10 with high prevalence reported in various parts of Nigeria. 12 Increased TB risk has been associated with a low CD4+-cell count (≤200 cells/µL) and high viral load (>200 copies/mL). 13 Together, HIV and Mycobacterium tuberculosis are the two leading causes of death among people living with HIV, accounting for one in four HIV-related deaths, 14,15 and continue to pose serious significant public health challenge in developing countries.…”